Back to mobile site

Canaccord Genuity Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)

May 14, 2024 8:01 AM EDT Send to a Friend
Canaccord Genuity analyst Kyle Mikson reiterated a Buy rating and $3.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD)The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login